Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.

Autoři	SALAJ Peter BRABEC Petr PENKA Miroslav POHLREICHOVÁ V. SMEJKAL Petr CETKOVSKÝ Petr DUŠEK Ladislav HEDNER U.
Rok publikování	2009
Druh	Článek v odborném periodiku
Časopis / Zdroj	Haemophilia
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Obor	Onkologie a hematologie
Klíčová slova	bleeding; dose; haemophilia; inhibitors; registry; rFVIIa
Popis	Identifying haemophilia patients with inhibitors for clinical trials is difficult due to the limited number of patients available. Registries are therefore being established as an additional means of data collection. The aim of this study was to investigate the effect of different recombinant activated factor VII (rFVIIa; NovoSeven((R))) dose ranges and dosing schedules on the incidence of re-bleeding in haemophilia patients with inhibitors. In this retrospective, uncontrolled study, data on the bleeding patterns of adult haemophilia patients with high responding inhibitors were analysed.